COVID-19 management strategies and vaccine recommendations for patients with hematologic malignancies, USA NY Presbyterian perspective

[lankisterguy]

This video replay is aimed at medical professionals, but seems easy to follow and has some specific details that we all could use (world wide CLL patients).

We are excited to announce this new webcast on COVID-19 management strategies and vaccine recommendations for patients with hematologic malignancies.

This accredited, on-demand activity features presentations that outline recommendations and special considerations for vaccinating patients with hematologic malignancies against COVID-19.

Click Here to view the video:

naccme.com/node/37063/cours...

Learning Objectives

After participating in this activity, learners should be better able to:

•Summarize the most recent updates in guidance for diagnosing, monitoring, and treating patients with hematologic malignancies during the COVID-19 pandemic

•Develop approaches to limit patient and provider exposure to SARS-CoV-2 while effectively managing hematologic malignancies

•Outline recommendations and special considerations for vaccinating patients with hematologic malignancies against COVID-19

-

Len

[Smakwater]

Had to look up USA NY Presbyterian Perspective -

Came up with Scottish Ecclesiastical Assertive Free Republic Democratic point of view.

Just having fun Len,

JM

[lankisterguy Volunteer in reply to Smakwater]

Sorry, I kept exceeding the limits of characters in the Title, if I would have had more space it would have said from the perspective of Dr. Michael Satlin, Weill Cornell Medicine at New York Presbyterian Hospital- that is quite a mouthful.Len

[Smakwater in reply to lankisterguy]

Even more fun!

[Davidcara]

Will view the video later today. Thank you for sharing lankisterguy

[neurodervish]

Thanks for sharing this Len. He mentioned the approval of BAM and ETE (bamlanivimab and etesevimab) for post-exposure prophylaxis (for immunocompromised, high risk and unvaccinated etc.). I missed this earlier, but I guess the approval came out in September. fda.gov/drugs/drug-safety-a... I wonder if the use of combo mAb therapies will become more common for Covid (as has already been shown for CLL treatments)?